Early Treatment Strategies for Mild‑to‑Moderate Ulcerative Colitis

Initial 5‑ASA‑Based Therapy

For patients with mild‑to‑moderate ulcerative colitis, initiate standard‑dose oral mesalamine (2–3 g/day) plus rectal mesalamine when disease is extensive or left‑sided to maximize remission rates while avoiding corticosteroid exposure. 1, 2
In ulcerative proctitis (rectum‑only disease), the first‑line recommendation is topical mesalamine (enemas or suppositories) because rectal administration achieves higher local drug concentrations. 2, 3
If topical mesalamine is ineffective or not tolerated, add oral 5‑ASA or substitute with rectal corticosteroids. 1, 3
Refractory proctitis should be escalated to oral corticosteroids, topical tacrolimus, Janus‑kinase (JAK) inhibitors, sphingosine‑1‑phosphate (S1P) agonists, or biologic therapy. 3

Begin standard‑dose oral mesalamine (2–3 g/day) plus rectal mesalamine to optimize induction of remission in extensive or left‑sided mild‑to‑moderate disease. 1, 2
Once‑daily oral mesalamine dosing is preferred over multiple daily doses because it improves patient adherence without compromising efficacy. 1, 2
Patients presenting with moderate symptom severity achieve better outcomes when early combined oral + rectal therapy is used rather than a step‑wise escalation approach. 1, 2

If adequate response is not achieved after 2–4 weeks, escalate to high‑dose mesalamine (>3 g/day) together with rectal mesalamine. 1, 2, 3
When no clinical improvement is observed within 2 weeks of optimized 5‑ASA therapy, initiate oral prednisolone. 3
Do not postpone corticosteroid initiation beyond 2–4 weeks, as prolonged suboptimal control increases the risk of disease progression and complications. 3

In moderate‑to‑severe ulcerative colitis that fails to respond to oral corticosteroids within 2 weeks, or when tapering fails, start advanced therapy (biologics or JAK inhibitors) to avoid repeated corticosteroid courses. 3
The therapeutic goal has shifted from merely achieving clinical response to attaining biochemical, endoscopic, and histologic remission to prevent long‑term complications. 3

Probiotics, curcumin, and fecal microbiota transplantation should not be used as primary therapy because evidence is insufficient and they may delay effective treatment. 1, 2
Budesonide MMX or controlled‑release ileal budesonide are not recommended as first‑line agents for mild‑moderate ulcerative colitis; standard‑dose oral mesalamine or diazo‑bonded 5‑ASA remain preferred. 1, 2
Corticosteroids must never be employed for long‑term maintenance; maintenance therapy should consist of 5‑ASA agents, immunomodulators, or advanced therapies. 3

Continue the same agent that successfully induced remission for maintenance, with the explicit exclusion of corticosteroids. 3
For patients who achieve remission with infliximab, adding a purine analogue (azathioprine or 6‑mercaptopurine) can be considered for maintenance, typically after induction with another agent. 3

For extensive or left‑sided colitis, begin combination therapy with oral mesalamine 2–3 g/day plus rectal mesalamine enemas rather than oral mesalamine alone, to achieve higher remission rates【4】.
Once‑daily oral mesalamine dosing is preferred over multiple daily doses because it improves adherence without reducing efficacy【4】.
In ulcerative proctitis (rectum‑only disease), the first‑line recommendation is rectal mesalamine suppositories, which provide higher local drug concentrations【4】.
Patients who value convenience over maximal effectiveness may opt for oral mesalamine instead of rectal therapy, acknowledging a modest reduction in efficacy【4】.
For proctosigmoiditis, when rectal therapy is selected, mesalamine enemas are preferred over oral mesalamine【4】.
Mesalamine enemas are more effective than rectal corticosteroid preparations for inducing remission in proctosigmoiditis【4】.
If patients wish to avoid the inconvenience of enemas, rectal corticosteroid foam can be used as an alternative, though it is less effective than mesalamine enemas【4】.

If an inadequate clinical response is observed after 2–4 weeks of standard‑dose therapy, escalate to high‑dose mesalamine (>3 g/day) combined with rectal mesalamine【4】.
Budesonide MMX or controlled‑release ileal budesonide should not be used as first‑line agents; standard‑dose oral mesalamine remains the preferred initial therapy【4】.

Low‑dose mesalamine (<2 g/day) is inferior to standard dosing and should be avoided【4】.

All statements are derived from the 2019 Gastroenterology evidence review (citation 4).